@article{85ae70f6bf7b449c8a1d2d8b0f700227,
title = "Patient advocacy and DSM-5",
abstract = "The revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM) provides a useful opportunity to revisit debates about the nature of psychiatric classification. An important debate concerns the involvement of mental health consumers in revisions of the classification. One perspective argues that psychiatric classification is a scientific process undertaken by scientific experts and that including consumers in the revision process is merely pandering to political correctness. A contrasting perspective is that psychiatric classification is a process driven by a range of different values and that the involvement of patients and patient advocates would enhance this process. Here we draw on our experiences with input from the public during the deliberations of the Obsessive Compulsive-Spectrum Disorders subworkgroup of DSM-5, to help make the argument that psychiatric classification does require reasoned debate on a range of different facts and values, and that it is appropriate for scientist experts to review their nosological recommendations in the light of rigorous consideration of patient experience and feedback.",
keywords = "Consumer advocacy, Diagnosis, Diagnostic and Statistical Manual of Mental Disorders, Nosology, Obsessive-compulsive and related disorders, Patient advocacy, Psychiatric classification",
author = "Stein, {Dan J.} and Phillips, {Katharine A.}",
note = "Funding Information: We wish to thank the Trichotillomania Learning Center (TLC) and its Scientific Advisory Board for their input during the development of the DSM-5 chapter on obsessive-compulsive and related disorders. DJS is supported by the Medical Research Council of South Africa. Funding Information: DJS has received research grants and/or consultancy honoraria from Abbott, Astrazeneca, Biocodex, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Takeda, Tikvah, and Wyeth. Katharine A. Phillips Financial Disclosure includes receipt of salary and/or research support in the past 12 months from the National Institute of Mental Health (salary and research funding), Forest Laboratories (medication only for a study sponsored and funded by the National Institute of Mental Health) and Transcept Pharmaceuticals (research funding). Katherine A Phillips provided Consulting for Janssen Research and Development and received honoraria, royalties, or travel reimbursement from Oxford University Press, Guilford Press, Merck Manual (future) and Up to Date (future). She also received speaking or grant reviewing honoraria and/or travel reimbursement from academic and federal institutions and from professional organizations and the free pass from potential future royalties.",
year = "2013",
month = may,
day = "17",
doi = "10.1186/1741-7015-11-133",
language = "English",
volume = "11",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central Ltd.",
number = "1",
}